Owners, management and financials
CVR: 27908047
Not available
Net result: DKK -3,000
BI HOLDING A/S (100%)
CVR · view owners
Ahmet Turan Kayhan
Board: Andrea Panzieri (chair) and 2 members
CVR · view management
Active
Founded 2 June 2004
CVR · view overview
0 employees
Annual report 2023 · average
Director registered: Ahmet Turan Kayhan
CVR · 31/01/2023
View the full event history
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR is a Danish company of the type Aktieselskab based in København K, founded in 2004. The company is registered under the industry Anden finansiel formidling i.a.n.. The management consists of Ahmet Turan Kayhan. The board consists of Andrea Panzieri (chair), Allan Funk Nissen and Ahmet Turan Kayhan. The company is owned by BI HOLDING A/S. According to the 2023 annual report, the company had an average of 0 employees. In 2025, the company reported a net result of DKK -3,000 compared with DKK 2,000 the year before. Equity in the 2025 report amounted to DKK 2,482,000.
Selskabets formål er som komplementar at deltage i K/S BI Biomedical Venture Annex I, K/S BI Biomedical Venture Annex II, K/S BI Biomedical Venture Annex III og K/S BI Biomedical Venture IV. Selskabet hæfter direkte, ubegrænset og solidarisk for K/S BI Biomedical Venture Annex I's, K/S BI Biomedical Venture Annex II's, K/S BI Biomedical Venture Annex III's og K/S BI Biomedical Venture IVs forpligtelser.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | -3 t. | 2.5 mio. | 2.5 mio. | - | |
| 202401/01/2024 – 31/12/2024 | - | 2 t. | 2.5 mio. | 2.5 mio. | - | |
| 202301/01/2023 – 31/12/2023 | - | 1 t. | 2.5 mio. | 2.5 mio. | 0 | |
| 202201/01/2022 – 31/12/2022 | 0 | -9 t. | 2.5 mio. | 2.5 mio. | 0 | |
| 202101/01/2021 – 31/12/2021 | 0 | -7 t. | 2.5 mio. | 2.5 mio. | 0 | |
| 202001/01/2020 – 31/12/2020 | 0 | -47 t. | 2.5 mio. | 2.5 mio. | - | |
| 201901/01/2019 – 31/12/2019 | - | -156 t. | 2.5 mio. | 2.5 mio. | - | |
| 201801/01/2018 – 31/12/2018 | - | -46 t. | 2.7 mio. | 2.7 mio. | - | |
| 201701/01/2017 – 31/12/2017 | - | -43 t. | 2.8 mio. | 2.7 mio. | - | |
| 201601/01/2016 – 31/12/2016 | - | -255 t. | 2.8 mio. | 2.8 mio. | - | |
| 201501/01/2015 – 31/12/2015 | - | 700 t. | 3.2 mio. | 3 mio. | - | |
| 201401/01/2014 – 31/12/2014 | - | 104 t. | 2.4 mio. | 2.3 mio. | - | |
| 201301/01/2013 – 31/12/2013 | - | -196 t. | 2.4 mio. | 2.2 mio. | - | |
| 201201/01/2012 – 31/12/2012 | - | 490 t. | 2.6 mio. | 2.4 mio. | - |
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR is 27908047.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR is owned by BI HOLDING A/S.
The management of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR consists of Ahmet Turan Kayhan.
The board of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR consists of Andrea Panzieri, Allan Funk Nissen and Ahmet Turan Kayhan, with Andrea Panzieri as chair.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR had an average of 0 employees in the 2023 financial year according to the annual report.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR was founded on 2 June 2004.
Claim this page to add your logo and social links. Free to get started.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2025. The net result was DKK -3,000.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2024. The net result was DKK 2,000.
As of April 10, 2025, Allan Funk Nissen has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of April 10, 2025, Mikael Kortegaard Larsen has left the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2023. The net result was DKK 1,000.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -9,000.
As of May 25, 2023, EY Godkendt Revisionspartnerselskab has stepped down as auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 31, 2023, Ahmet Turan Kayhan has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 31, 2023, Kurt Hangaard has left the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 31, 2023, Ahmet Turan Kayhan is registered as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 31, 2023, Kurt Hangaard has stepped down as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -7,000.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2020. Revenue came to DKK 0, and the net result was DKK -47,000.
As of April 15, 2021, EY Godkendt Revisionspartnerselskab has been appointed auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of April 15, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2019. Gross profit came to DKK -12,000, and the net result was DKK -156,000.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2018. Gross profit came to DKK -12,000, and the net result was DKK -46,000.
As of January 7, 2019, Kurt Hangaard has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 7, 2019, Sanne Fredenslund has left the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 7, 2019, Kurt Hangaard is registered as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 7, 2019, Sanne Fredenslund has stepped down as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 7, 2018, Sanne Fredenslund has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 7, 2018, Lars Thomas Gunnarsson has left the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 7, 2018, Sanne Fredenslund is registered as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 7, 2018, Lars Thomas Gunnarsson has stepped down as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2017. Gross profit came to DKK -21,000, and the net result was DKK -43,000.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2016. Gross profit came to DKK -17,000, and the net result was DKK -255,000.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2015. Gross profit came to DKK -28,000, and the net result was DKK 700,000.
As of April 28, 2016, Lars Thomas Gunnarsson has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of April 28, 2016, Kenneth Bering Hansen has left the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of April 28, 2016, Lars Thomas Gunnarsson is registered as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of April 28, 2016, Kenneth Bering Hansen has stepped down as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2014. Gross profit came to DKK -16,000, and the net result was DKK 104,000.
As of December 10, 2014, Kenneth Bering Hansen has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of December 10, 2014, Andrea Panzieri has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of December 10, 2014, Mikael Kortegaard Larsen has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of December 10, 2014, Kenneth Bering Hansen is registered as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of December 10, 2014, Bo Foged has stepped down as adm. dir. of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2013. Gross profit came to DKK -16,000, and the net result was DKK -196,000.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR has published its annual report for 2012. Gross profit came to DKK -34,000, and the net result was DKK 490,000.
As of October 13, 2011, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of October 13, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of September 16, 2011, Torben Arnth Nielsen has left the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of May 2, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 11, 2010, Bo Foged is registered as adm. dir. of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 11, 2010, Thomas Tscherning has stepped down as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of April 29, 2009, EY Godkendt Revisionspartnerselskab has stepped down as auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 7, 2009, Thomas Tscherning is registered as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 7, 2009, Jesper Zeuthen has stepped down as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of January 2, 2009, Nils Hougaard Christensen has left the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of October 9, 2008, Torben Arnth Nielsen has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of October 9, 2008, Niels Burtenshaw Thuesen has left the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 3, 2008, Bjarne Thorup has left the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of May 26, 2008, EY Godkendt Revisionspartnerselskab has been appointed auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of May 26, 2008, CJ Partnership I/S has stepped down as auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of May 20, 2005, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of December 8, 2004, BI HOLDING A/S is registered as an owner of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR with an ownership share of 100%.
As of June 2, 2004, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 2, 2004, CJ Partnership I/S has been appointed auditor of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 2, 2004, Niels Burtenshaw Thuesen has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 2, 2004, Nils Hougaard Christensen has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 2, 2004, Bjarne Thorup has joined the board of directors of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
As of June 2, 2004, Jesper Zeuthen is registered as director of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR.
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR was founded on June 2, 2004.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at drive forretning med digital markedsføring og strategi samt enhver i forbindelse hermed stående virksomhed.
Companies in the same industry and area
CVR 38168487
CVR 38168509
CVR 45365123
CVR 42904007
CVR 41201886
